Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445225 | 0.96 | IKBKB (0.37) | IKBKBPTPN11ADRB2ADRB1ADRB3 | |
| SCHEMBL5449569 | 0.96 | IKBKB (0.37) | IKBKBPTPN11ADRB2ADRB1ADRB3 | |
| SCHEMBL5445988 | 0.90 | IKBKB (0.38) | IKBKBPTPN11ADRB2ADRB1ADRB3 | |
| SCHEMBL5453971 | 0.84 | PTPN11 (0.37) | IKBKBPTPN11ADRB2ADRB1ADRB3 | |
| SCHEMBL5455507 | 0.84 | PTPN11 (0.37) | IKBKBPTPN11ADRB2ADRB1ADRB3 | |
| SCHEMBL5452187 | 0.83 | NPC1 (0.44) | IKBKBPTPN11HTTSMN1; SMN2 | |
| SCHEMBL5451337 | 0.81 | ADRB2 (0.40) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5448551 | 0.79 | PTPN11 (0.38) | IKBKBPTPN11ADRB2ADRB1ADRB3 | |
| SCHEMBL5451323 | 0.78 | ADRB2 (0.55) | ADRB2ADRB1ADRB3 | |
| SCHEMBL4802684 | 0.76 | CA1 (0.48) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249630-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | US | disclosed |
| EP-1478620-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003072539-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | IKBKB 4361/4885PTPN11 4008/4885ADRB2 89/4885 |
| US-20070249630-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | IKBKB 4361/4885PTPN11 4008/4885ADRB2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.